Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
2012-09-07
(Press-News.org) Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.
According to the American Cancer Society, lung cancer is the number one cause of cancer deaths in men and women each year. The current standard treatment for advanced NS-NSCLC patients, the most common form of advanced NSCLC, is either Pac+Cb+B or pemetrexed plus cisplatin. This trial sought to define a new standard of care by comparing Pac+Cb+B to the experimental chemotherapy regimen Pem+Cb+B to determine if either improved overall survival for late-stage lung cancer patients. Pemetrexed plus cisplatin was not tested in this trial.
The 939 patients were randomized to receive one of the two treatment arms every three weeks for up to four cycles. The patients received the same arm for each cycle. Overall survival was not statistically different between the two arms, 12.6 months in Pem+Cb+ Bev versus 13.4 months for the Pac+Cb+B arm, The
experimental arm of Pem+Cb+Bev led to a increase in time before progression of disease (PFS) compared with the standard arm of Pac+ Cb+Bev—6 months versus 5.6 months, respectively.
"The fact that there was no improvement in survival with the experimental regimen was disappointing, but these findings are important as we continue to navigate ways to improve survival for this devastating disease," said Jyoti Patel, MD, lead author of the study and an associate professor in Medicine-Hematology/Oncology at Northwestern University in Chicago. "It is important to note that both regimens demonstrated tolerability, although their toxicities differed. These differences can be important for our patients."
INFORMATION:
The abstract, "A Randomized, Open-label, Phase 3, Superiority Study of Pemetrexed (Pem) + Carboplatin (Cb) + Bevacizumab (B) Followed by Maintenance Pem + B versus Paclitaxel (Pac) + Cb + B Followed by Maintenance B in Patients (pts) with Stage IIB or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC)," will be presented during the Plenary Session at 12:30 p.m., Central time on September 7, 2012. To speak with Jyoti Patel, MD, please call Michelle Kirkwood or Nicole Napoli on September 6-8, 2012, in the press office at the Chicago Marriott Downtown Magnificent Mile at 312-595-3188. You may also email them at michellek@astro.org or nicolen@astro.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-09-07
SAN ANTONIO (Sept. 6, 2012) — RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.
Santanu Bose, Ph.D., of the School of Medicine, is the inventor on a pending U.S. patent of RSV as an oncolytic therapy. This represents a new use for the virus. Bandana Chatterjee, Ph.D., of the School of Medicine and the South Texas Veterans Health Care System, is the co-inventor. Oncolytic ...
2012-09-07
Every ten years or so, someone will make the observation that there is a lack of political diversity among psychological scientists and a discussion about what ought to be done ensues. The notion that the field discriminates against and is skewed toward a liberal political perspective is worthy of concern; scholars, both within and outside the field, have offered various solutions to this diversity problem.
As psychological scientists Yoel Inbar and Joris Lammers point out, however, we have few of the relevant facts necessary to understand and address the issue.
In ...
2012-09-07
Pick your poison: sun exposure that leads to skin cancer or low physical activity that leads to obesity? In fact, a University of Colorado Cancer Center study published this week in the journal Preventing Chronic Disease shows that parents' concern about skin cancer doesn't make them keep their kids indoors.
"Actually, our hypothesis was the opposite – that if parents were concerned about skin cancer they wouldn't let their children go out as much," says Alexander Tran, summer fellow working with Lori Crane, PhD, CU Cancer Center investigator and chair of the Department ...
2012-09-07
GAINESVILLE, Fla. — University of Florida scientists publishing the first study on butterflies and moths of Guantanamo Bay Naval Station have discovered vast biodiversity in an area previously unknown to researchers.
Appearing in the Bulletin of the Allyn Museum Sept. 5, the study creates a baseline for understanding how different plant and animal species have spread throughout the Caribbean.
"Biodiversity studies are extremely important because they give us clues about where things were and how they evolved over time so we can better understand what may happen in ...
2012-09-07
CAMBRIDGE, MA -- Competition is a strong driving force of evolution for organisms of all sizes: Those individuals best equipped to obtain resources adapt and reproduce, while others may fall by the wayside. Many organisms — mammals, birds and insects, for instance — also form cooperative social structures that allow resources to be defended and shared within a population.
But surprisingly, even microbes, which are thought to thrive only when able to win the battle for resources against those nearest to them, have a somewhat sophisticated social structure that relies on ...
2012-09-07
A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago.
This ...
2012-09-07
Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival compared to non-Hispanic white patients, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The ...
2012-09-07
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) ...
2012-09-07
COLLEGE PARK, Md. - From a public policy point of view, the national debt accumulation since President Obama took office is largely a result of policies put in place prior to his inauguration, says a new analysis by University of Maryland expert Philip Joyce. He adds that Obama's policies will make little impact in the debt over the next decade.
"The best that can be said about presidential fiscal policies thus far is that they would slow the bleeding, but they neither would stop it nor would they do much to heal the patient," Joyce says.
The size of the debt has been ...
2012-09-07
Today, technicians in Minnesota will begin to position the first block of a detector that will be part of the largest, most advanced neutrino experiment in North America.
The NuMI Off-Axis Neutrino Appearance experiment – NOvA for short – will study the properties of neutrinos, such as their masses, and investigate whether they helped give matter an edge over antimatter after both were created in equal amounts in the big bang. The experiment is on track to begin taking data in 2013.
"This is a significant step toward a greater understanding of neutrinos," said Marvin ...
LAST 30 PRESS RELEASES:
[Press-News.org] Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
